Recent Updates
Recently added Catalysts

interleukin-4 PE38KDEL cytotoxin

Phase 2

Brain and Central Nervous System Tumors | Monoclonal antibody | Oncology |Neurocrine Biosciences, Inc.|Last Updated: Jul 18, 2013

Success Probability
Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
Premium
Market & Valuation
rNPV $3.2B
Market Size $9.4B
Revenue Basis $1.6B
Competitors 6
Premium
Trial Design
UNCONTROLLEDBiomarker
Total Trials1
Total Enrollment -
FDA Designations
No designations recorded
Clinical Trials (1)
NCT IDTitlePhaseStatusEnrollmentVelocityDesignStartCompletionLast UpdatedSitesCountries
NCT00014677NBI-3001 Followed by Surgery in Treating Patients With Recurrent Glioblastoma MultiformePHASE2 COMPLETED -Mar 1, 2001Jul 1, 2008Jul 18, 20134 United States
Unlock Drug Trial Details
Study Design & Arms
PurposeTREATMENT
Interventions
NameTypeDescription
interleukin-4 PE38KDEL cytotoxinBIOLOGICAL -
conventional surgeryPROCEDURE -
Unlock Study Design Details
Eligibility Criteria
Age Range18 Years — N/A
SexALL
Healthy VolunteersNo
Study Sites4

DISEASE CHARACTERISTICS: Histologically confirmed recurrent or progressive glioblastoma multiforme Previously treated with cytoreductive surgery Unilateral, unifocal tumor with a volume of 5-80 mL Not eligible for further radiotherapy due to prior external beam radiotherapy No multifocal, brain stem...

Countries:United States
Unlock Eligibility Criteria